Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Violations Trigger Bans On 73 Drug Advertisements

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has released a report on illegal pharmaceutical, medical device and health food advertisements identified during the June to December period of 2008. This report is a compilation of reports sent from local food and drug administrative bodies that covered 24,565 illegal pharmaceutical advertisements, 1,532 illegal medical device advertisements and 15,196 illegal health food advertisements. Ten provinces, including Jilin, Shanxi, and Qinghai, have revoked licenses for a total of 73 advertisements due to their obvious digression from previously approved content. These illegal, highly visible advertisements claimed or guaranteed product results without scientific evidence. In addition, some illegal pharmaceutical or medical device ads seriously deceived or mislead consumers by using patients or medical institutions for product testimony. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071117

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel